SCHEDULE 13G/A: Redmile Group and Jeremy C. Green Disclose 4.7% Passive Stake in Silence Therapeutics plc

Redmile Group, LLC and its principal, Jeremy C. Green, have reported a combined beneficial ownership of 4.7% of Silence Therapeutics plc's Ordinary Shares, held through private investment vehicles.

Summary

• Redmile Group, LLC and its principal, Jeremy C. Green, have filed an Amendment No. 1 to Schedule 13G, disclosing their beneficial ownership in Silence Therapeutics plc.
• As of March 31, 2025, the reporting persons collectively beneficially own 6,644,841 Ordinary Shares, representing 4.7% of the company's outstanding shares.
• This ownership is comprised of 2,214,947 American Depositary Shares (ADSs), with each ADS representing three Ordinary Shares.
• The percentage is calculated based on 141,674,074 Ordinary Shares outstanding as of January 31, 2025, as reported by Silence Therapeutics plc in its Form 10-K for the fiscal year ended December 31, 2024, filed on February 27, 2025.
• The shares are held by certain private investment vehicles managed by Redmile Group, LLC, and the beneficial ownership is disclaimed by Redmile Group, LLC and Mr. Green except to the extent of their pecuniary interest.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would significantly alter the company's operational or financial outlook. The presence of a significant investor is generally neutral to slightly positive.

Positives

• The disclosure of a significant stake by Redmile Group, LLC, a notable investment firm, could be interpreted as a vote of confidence in Silence Therapeutics plc's long-term prospects, even if the stake is passive.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership by Redmile Group, LLC and Jeremy C. Green and does not contain any forward-looking statements or guidance from Silence Therapeutics plc.

Industry Context

This filing represents a standard disclosure of passive beneficial ownership by an investment firm in a publicly traded company. It does not provide specific insights into broader industry trends or competitive dynamics beyond the fact that a significant investment firm holds a stake in Silence Therapeutics plc.

Stakeholder Impact

• Shareholders: The disclosure informs existing and potential shareholders about a significant passive investor's stake in the company, which may influence market perception.

Key Dates

Keywords

Silence Therapeutics, Redmile Group, Jeremy C. Green, Schedule 13G, beneficial ownership, Ordinary Shares, ADSs, investment, passive stake